Tim joined LongeVC as a Venture Partner, leveraging more than 25 years of financial leadership across publicly traded biopharmaceutical companies to identify limited partners and accelerate high-potential investment opportunities.
Timothy Morris
Venture Partner
Tim’s executive experience spans CFO and COO roles at firms including Humanigen Inc. (Nasdaq: HGEN), Iovance Biotherapeutics (Nasdaq: IOVA)—where he supported the approval of AMTAGVI, the first cell therapy for solid tumors—AcelRx (Nasdaq:ACRX), VIVUS Inc. (Nasdaq: VVUS), and Questcor Pharmaceuticals (Nasdaq: QCOR).
Over his career, he has raised more than $2.7 billion in equity and convertible securities across eight companies, including two IPOs. He has executed over 100 strategic transactions totaling $5.7 billion in aggregate value—ranging from M&A, licensing and corporate restructurings.
As an operator, Tim played a key role in four NDA approvals and two MAA approvals, including the U.S. launch of QSYMIA for obesity and commercial preparations for DSUVIA. His expertise spans capital formation, commercial strategy, manufacturing,
and business development—making him a powerful ally in building value from early innovation to global scale.
He currently sits on the Boards of DBV Technologies (Nasdaq: DBVT), Aquestive Therapeutics (Nasdaq: AQST), Humanetics Corporation, and Univercells SA (private).
Over his career, he has raised more than $2.7 billion in equity and convertible securities across eight companies, including two IPOs. He has executed over 100 strategic transactions totaling $5.7 billion in aggregate value—ranging from M&A, licensing and corporate restructurings.
As an operator, Tim played a key role in four NDA approvals and two MAA approvals, including the U.S. launch of QSYMIA for obesity and commercial preparations for DSUVIA. His expertise spans capital formation, commercial strategy, manufacturing,
and business development—making him a powerful ally in building value from early innovation to global scale.
He currently sits on the Boards of DBV Technologies (Nasdaq: DBVT), Aquestive Therapeutics (Nasdaq: AQST), Humanetics Corporation, and Univercells SA (private).
Washington D.C., US
The Future Belongs to Biotech Founders
© All Rights Reserved, 2025
© All Rights Reserved, 2025
get in touch
social
newsletter
